Apellis currently accepts requests for grants and giving support pertaining to the following therapeutic areas and patient communities:

• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Geographic Atrophy (GA)/Dry Macular Degeneration (AMD)
• Amyotrophic lateral sclerosis (ALS)
• Immune complex membranoproliferative glomerulonephritis (IC-MPGN) and C3 glomerulopathy (C3G)
• Cold Agglutinin Disease (CAD)
• Hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA)
• Patient organizations working in areas that overlap with our medicines and pipeline
• Other investigational science observed within Apellis’ pipeline (particularly for non-CME grants)

Apellis is currently not accepting Independent Medical Education (IME) grant applications for Paroxysmal Nocturnal Hemoglobinuria (PNH).

Please continue to check back for updates. This list is evaluated and updated regularly. Apellis reserves the right to review or modify therapeutic areas of interest at any time without notice.